SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular ...
Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...
A meta-analysis found that patients with early and intermediate-stage hepatocellular carcinoma who received external beam radiation therapy (EBRT) demonstrated better local control and ...
First-line transarterial chemoembolization combined with radiotherapy is associated with improved survival among patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback